As per the research conducted by GME, the Osteoporosis Drugs Market will grow with a CAGR value of 3.7 percent by 2026. The increase in the incidence of osteoporosis is a significant trigger contributing to the advancement of the osteoporosis drug market. Other factors behind the expansion of the osteoporosis drugs market include an increase in the global elderly demographics and a rise in the acceptance of sedentary lifestyles.
Browse 151 Market Data Tables and 111 Figures spread through 181 Pages and in-depth TOC on “Osteoporosis Drugs Market - Forecast to 2026"
https://www.globalmarketestimates.com/market-report/global-osteoporosis-drugs-market-3154
By Product (Branded [Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM), Rank Ligand Inhibitors, and Others] and Generics), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), By Region (North America, Asia Pacific, CSA, Europe, and The Middle East and Africa); End-User, Landscape, Company Market Share Analysis, and Competitor Analysis
Key Market Insights
- Through the forecast period, emerging economies with strong growth prospects are supposed to provide attractive opportunities.
- Branded medicines are likely to be the highest-selling products because of increased spending by key players in the research & development activities of innovative novel drugs.
- Parenteral route of administration is foreseen to hold its predominance due to higher bioavailability and a faster mechanism of action.
- Hospital pharmacy is presumed to lead because of the surge in the proportion of patients attending hospitals forosteoporosis care.
- North America is foreseen tolead this market because the government has also been organizing awareness.
- Amgen Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck & Co. Inc., Novo Nordisk A/S, Novartis AG, Pfizer, Radius Health Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Ltd., and Teva Pharmaceutical Industries Ltd. among others, are the top players in the osteoporosis drugs market.
Browse the Report @https://www.globalmarketestimates.com/market-report/global-osteoporosis-drugs-market-3154
Product Outlook (Revenue, USD Billion, 2021-2026)
- Branded
- Bisphosphonates
- Parathyroid Hormone Therapy
- Calcitonin
- Selective Estrogen Inhibitors Modulator (SERM)
- Rank Ligand Inhibitors
- Others
- Generics
Route of Administration Outlook (Revenue, USD Billion, 2021-2026)
- Oral
- Parenteral
Distribution Channel Outlook (Revenue, USD Billion, 2021-2026)
- Hospital Pharmacies
- Retail Pharmacies
- Others
Regional Outlook (Revenue, USD Billion, 2021-2026)
North America
- The U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Rest of APAC
Central & South America
- Brazil
- Argentina
- Rest of CSA
Middle East & Africa
- Saudi Arabia
- UAE
- Rest of MEA
Contact: Tracy Simon
Email address: tracy.simon@globalmarketestimates.com
Phone Number: +16026667238
Website: https://www.globalmarketestimates.com/
Check our Latest Blogs: https://www.globalmarketestimates.com/blog-posts.php
0 Comments